Application Research of Multimodal Graph Neural Networks in Cancer Drug Response Prediction

This article proposes a drug-gene interaction modeling method based on multimodal graph neural networks and cross-attention mechanisms for cancer drug response prediction. The method integrates heterogeneous data such as drug molecular structures and cell line gene expression profiles, extracts molecular features via graph neural networks, achieves deep interaction between modalities through cross-attention, and proves its effectiveness through ablation experiments and cross-dataset validation. In addition, the model has interpretability and uncertainty quantification capabilities, providing a new technical path for precision cancer medicine.

Drug Response Prediction (DRP) aims to predict a patient's sensitivity to specific anti-cancer drugs based on their molecular characteristics. This task faces multiple challenges: the interaction between drugs and cancer cells involves multiple biological levels such as genomics and transcriptomics; there is significant heterogeneity among different cancer types and individual patients; available experimental data are sparse and have batch effects. Therefore, it is crucial to build prediction models that can integrate multi-source heterogeneous data and have strong generalization capabilities.

This study adopts a multimodal learning framework, integrating two types of data: drug molecular structures and cell line gene expression profiles. The drug modality is represented as a molecular graph (atoms as nodes, chemical bonds as edges), and structural features are extracted via graph neural networks; the gene expression modality processes high-dimensional transcriptome data through fully connected networks. The key innovation lies in the introduction of a cross-attention mechanism to achieve deep interaction between drug and gene features; its attention weight matrix can reveal relevant features and improve the model's interpretability.

The model validation system includes: ablation experiments to quantify the contribution of each component; statistical significance tests to exclude the impact of random fluctuations; an uncertainty estimation module to provide prediction confidence intervals. To verify generalization capability, the model was tested on multiple independent datasets, proving that it can handle distribution shifts from different laboratory experimental conditions, cell line sources, and drug batches, laying a foundation for clinical applications.

The uncertainty quantification module uses ensemble learning or Bayesian neural network methods to provide prediction confidence scores, which can mark high-uncertainty samples for expert review, forming a human-machine collaborative decision-making process. The interpretability of the cross-attention mechanism is reflected in: through visualizing attention weights, researchers can discover key genes related to drug sensitivity, suggesting new drug targets or drug resistance mechanisms, and aiding drug design and combination therapy strategies.

Future exploration directions: integrate more modalities such as protein structures, epigenetic data, and clinical records; develop cross-domain transfer learning methods to adapt to new cancer types or drugs; combine prediction models with experimental design optimization to accelerate drug screening. Conclusion: Multimodal graph neural networks open up a new path for cancer drug response prediction. By integrating heterogeneous data, introducing interpretable mechanisms, and conducting strict validation, they can extract actionable insights from biomedical data, which is expected to promote the development of precision oncology and benefit cancer patients.